392 related articles for article (PubMed ID: 27063942)
1. Targeting the cannabinoid CB2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice.
Palomo-Garo C; Gómez-Gálvez Y; García C; Fernández-Ruiz J
Pharmacol Res; 2016 Aug; 110():181-192. PubMed ID: 27063942
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of Parkinson's Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein Pathology.
Xiong Y; Neifert S; Karuppagounder SS; Stankowski JN; Lee BD; Grima JC; Chen G; Ko HS; Lee Y; Swing D; Tessarollo L; Dawson TM; Dawson VL
eNeuro; 2017; 4(2):. PubMed ID: 28321439
[TBL] [Abstract][Full Text] [Related]
3. Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease.
Gómez-Gálvez Y; Palomo-Garo C; Fernández-Ruiz J; García C
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():200-8. PubMed ID: 25863279
[TBL] [Abstract][Full Text] [Related]
4. Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease.
Tozzi A; Durante V; Bastioli G; Mazzocchetti P; Novello S; Mechelli A; Morari M; Costa C; Mancini A; Di Filippo M; Calabresi P
Neurobiol Dis; 2018 Oct; 118():1-8. PubMed ID: 29908325
[TBL] [Abstract][Full Text] [Related]
5. LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.
Sloan M; Alegre-Abarrategui J; Potgieter D; Kaufmann AK; Exley R; Deltheil T; Threlfell S; Connor-Robson N; Brimblecombe K; Wallings R; Cioroch M; Bannerman DM; Bolam JP; Magill PJ; Cragg SJ; Dodson PD; Wade-Martins R
Hum Mol Genet; 2016 Mar; 25(5):951-63. PubMed ID: 26744332
[TBL] [Abstract][Full Text] [Related]
6. Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3β activity.
Lin CH; Lin HI; Chen ML; Lai TT; Cao LP; Farrer MJ; Wu RM; Chien CT
Hum Mol Genet; 2016 May; 25(10):1965-1978. PubMed ID: 26931464
[TBL] [Abstract][Full Text] [Related]
7. Parkinson's Disease-Linked LRRK2-G2019S Mutation Alters Synaptic Plasticity and Promotes Resilience to Chronic Social Stress in Young Adulthood.
Matikainen-Ankney BA; Kezunovic N; Menard C; Flanigan ME; Zhong Y; Russo SJ; Benson DL; Huntley GW
J Neurosci; 2018 Nov; 38(45):9700-9711. PubMed ID: 30249796
[TBL] [Abstract][Full Text] [Related]
8. Human LRRK2 G2019S mutation represses post-synaptic protein PSD95 and causes cognitive impairment in transgenic mice.
Adeosun SO; Hou X; Zheng B; Melrose HL; Mosley T; Wang JM
Neurobiol Learn Mem; 2017 Jul; 142(Pt B):182-189. PubMed ID: 28487191
[TBL] [Abstract][Full Text] [Related]
9. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
[TBL] [Abstract][Full Text] [Related]
10. LRRK2 modifies α-syn pathology and spread in mouse models and human neurons.
Bieri G; Brahic M; Bousset L; Couthouis J; Kramer NJ; Ma R; Nakayama L; Monbureau M; Defensor E; Schüle B; Shamloo M; Melki R; Gitler AD
Acta Neuropathol; 2019 Jun; 137(6):961-980. PubMed ID: 30927072
[TBL] [Abstract][Full Text] [Related]
11. LRRK2 G2019S Induces Anxiety/Depression-like Behavior before the Onset of Motor Dysfunction with 5-HT
Lim J; Bang Y; Choi JH; Han A; Kwon MS; Liu KH; Choi HJ
J Neurosci; 2018 Feb; 38(7):1611-1621. PubMed ID: 29305532
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoid CB(1) receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice.
González S; Mena MA; Lastres-Becker I; Serrano A; de Yébenes JG; Ramos JA; Fernández-Ruiz J
Brain Res; 2005 Jun; 1046(1-2):195-206. PubMed ID: 15882845
[TBL] [Abstract][Full Text] [Related]
13. Parkinson's disease-like burst firing activity in subthalamic nucleus induced by AAV-α-synuclein is normalized by LRRK2 modulation.
Andersen MA; Christensen KV; Badolo L; Smith GP; Jeggo R; Jensen PH; Andersen KJ; Sotty F
Neurobiol Dis; 2018 Aug; 116():13-27. PubMed ID: 29680709
[TBL] [Abstract][Full Text] [Related]
14. A dual inhibitor targeting HMG-CoA reductase and histone deacetylase mitigates neurite degeneration in
Lin CH; Lin HY; Fang JM; Chen CC
Aging (Albany NY); 2020 Nov; 12(24):25581-25598. PubMed ID: 33231564
[TBL] [Abstract][Full Text] [Related]
15. Neuronal Firing and Glutamatergic Synapses in the Substantia Nigra Pars Reticulata of LRRK2-G2019S Mice.
Sitzia G; Skiteva O; Chergui K
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358985
[TBL] [Abstract][Full Text] [Related]
16. Mild Chronic Colitis Triggers Parkinsonism in LRRK2 Mutant Mice Through Activating TNF-α Pathway.
Lin CH; Lin HY; Ho EP; Ke YC; Cheng MF; Shiue CY; Wu CH; Liao PH; Hsu AY; Chu LA; Liu YD; Lin YH; Tai YC; Shun CT; Chiu HM; Wu MS
Mov Disord; 2022 Apr; 37(4):745-757. PubMed ID: 34918781
[TBL] [Abstract][Full Text] [Related]
17. The endocannabinoid system as a target for the treatment of motor dysfunction.
Fernández-Ruiz J
Br J Pharmacol; 2009 Apr; 156(7):1029-40. PubMed ID: 19220290
[TBL] [Abstract][Full Text] [Related]
18. Homozygous mutation of the LRRK2 ROC domain as a novel genetic model of parkinsonism.
Chen ML; Wu RM
J Biomed Sci; 2022 Aug; 29(1):60. PubMed ID: 35965315
[TBL] [Abstract][Full Text] [Related]
19. Altered Motor Performance, Sleep EEG, and Parkinson's Disease Pathology Induced by Chronic Sleep Deprivation in Lrrk2
Liu X; Yu H; Wang Y; Li S; Cheng C; Al-Nusaif M; Le W
Neurosci Bull; 2022 Oct; 38(10):1170-1182. PubMed ID: 35612787
[TBL] [Abstract][Full Text] [Related]
20. Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging.
Walker MD; Volta M; Cataldi S; Dinelle K; Beccano-Kelly D; Munsie L; Kornelsen R; Mah C; Chou P; Co K; Khinda J; Mroczek M; Bergeron S; Yu K; Cao LP; Funk N; Ott T; Galter D; Riess O; Biskup S; Milnerwood AJ; Stoessl AJ; Farrer MJ; Sossi V
J Parkinsons Dis; 2014; 4(3):483-98. PubMed ID: 25000966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
